Since NNMT-driven SIRT1 activation could potentially counteract HDAC inhibition, future studies should explore whether NNMT inhibitors could enhance the therapeutic efficacy of HDAC inhibitors in osteosarcoma treatment. The gene discussed is HDAC9; the disease is osteosarcoma.